Pancreatic cancer has proven one of the most challenging cancers to treat, with low survival rates and limited treatment options. However, a wave of innovative clinical trials is now offering new possibilities for pancreatic cancer patients, including those affected by 9/11-related exposures. Advances in targeted therapies, precision medicine, and immunotherapy are changing the world of pancreatic cancer care. For individuals diagnosed after being exposed in the aftermath of the 9/11 terrorist attacks, these advances bring with them hope for more positive outcomes and better treatment options for individuals diagnosed with pancreatic cancer.
